AUTHORS
Rudra Prasad Dutta, PhD, Adolfo Aleman, PhD2, Alessia D'Anna, Postdoctoral Fellow3, Junia Vieira, Postdoctoral Fellow4, Alison S. Park, N/A5, Katerina Kappes, N/A6, Alessandro Lagana, PhD7, Samir Parekh, MD8
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Background: High-risk multiple myeloma (MM) remains an unmet clinical problem, with genomic subgroups such as t(4;14) combined with 1q gain/amplification relapsing early despite modern therapy and lacking lesion-directed treatment strategies. Our prior network-based analysis of the MMRF CoMMpass dataset identified CDC42BPA (CDC42 Binding Protein Kinase Alpha) as a candidate driver gene and regulator of MMSET/NSD2 signaling in t(4;14) MM (Laganà et al., 2018). Because CDC42BPA encodes MRCKα, a druggable CDC42 effector kinase, we sought to determine whether this dependency is enriched in lesion-defined high-risk disease and whether MRCK inhibition represents a therapeutic strategy for this subgroup.
Methods: CDC42BPA expression and prognostic significance were evaluated in multiple myeloma (MM) using the CoMMpass cohort. An independent high-risk single-cell MM dataset was analyzed to identify lesion-specific malignant populations, comparing t(4;14)+1q cells with other malignant subsets to determine selective CDC42BPA upregulation and hub-gene prioritization. CDC42BPA knockout (KO) was generated to define its functional role, followed by RNA sequencing and Western blot analyses. Based on these findings, two t(4;14) MM cell lines (H929 and OPM-2) were treated with the selective MRCK inhibitor BDP-9066. Cell viability, apoptosis, and gene expression were assessed using CellTiter-Glo, Annexin V flow cytometry, and qPCR.
Results: CDC42BPA encodes a serine/threonine protein kinase and key downstream effector of CDC42 that regulates cytoskeletal reorganization and cell migration. Expanded analysis of CoMMpass patient data confirmed that CDC42BPA expression is enriched in patients harboring the t(4;14) translocation and 1q gain/amplification, defining a high-risk cytogenetic subgroup with elevated CDC42BPA dependency (Bhalla et al, 2021). Consistent with this bulk genomic signal, lesion-resolved single-cell analysis in an independent cohort of 104 NDMM patients re-nominated CDC42BPA as a top upregulated hub gene in t(4;14)+1q malignant populations, supporting its relevance in single-cell-defined high-risk tumor cells. CRISPR-mediated CDC42BPA KO in H929 cells with t(4;14)+1q gain showed significantly reduced proliferation compared to wild-type controls (p ≤ 0.05), confirming a functional requirement for CDC42BPA in MM cell growth. Bulk RNA-seq revealed a transcriptional program of apoptotic priming: the anti-apoptotic genes MCL1, BIRC3, BCL3, and NFKBIA were downregulated (fold change >2; FDR≤ 0.05), while the cell cycle arrest and stress response genes CDKN1A, GADD45A, and GADD45B were upregulated. Knockout cells also showed reduced expression of CXCR4, a chemokine receptor governing MM cell homing and retention within the bone marrow niche, suggesting that CDC42BPA loss may impair microenvironment dependent survival signaling. Notably, FGFR3, the second key oncogene dysregulated by the t(4;14) translocation alongside MMSET, was also downregulated following CDC42BPA loss, indicating that CDC42BPA may help sustain the core t(4;14) oncogenic program in addition to driving NF-κB dependent survival signaling. Western blot analysis confirmed a marked decrease in phosphorylated NF-κB alongside reduced MCL1 protein, providing direct biochemical evidence that CDC42BPA sustains NF-κB pathway activation in t(4;14) MM. Finally, to translate this genetic dependency into a druggable therapeutic strategy, we tested the selective MRCK inhibitor BDP-9066 in MM cells. BDP-9066 phenocopied genetic CDC42BPA loss, inducing significant cytotoxicity (OPM-2 IC50 5.5±0.8 µM; H929 IC50 15.0±0.7 µM) with dose-dependent (2.5-20 µM) increases in cleaved PARP and cleaved caspase 3 in both H929 and OPM-2 cells.
Conclusion: These findings build on our group's prior identification of CDC42BPA as a t(4;14)/MMSET-associated driver gene by establishing that CDC42BPA sustains proliferation, survival, and microenvironment interaction of t(4;14) MM cells through activation of NF-κB signaling. The convergence of CoMMpass, lesion-resolved single-cell nomination, genetic depletion, and pharmacologic inhibition supports CDC42BPA/MRCK as a targetable dependency in high-risk t(4;14)+1q MM. These data provide pharmacological proof of concept that MRCK inhibition, exemplified by BDP-9066, represents a rational therapeutic strategy for high-risk, t(4;14)/1q-gain multiple myeloma.
DISCLOSURES
Rudra Prasad Dutta, PhD: No relevant conflicts of interest to declare.